Insider · CIK 0002005463
Ross Muken
Files at SOPH (SOPHiA GENETICS SA). First filing Mar 20, 2026, latest Oct 7, 2026.
In brief
Ross Muken files SEC Form 4 as CEO, director and president at SOPH (SOPHiA GENETICS SA). Since Mar 20, 2026, Ross Muken has reported 0 open-market buys worth $0 and 11 open-market sells worth $250k, the latest filed on Oct 7, 2026.
A track record needs three past buys with six months of prices behind them; Ross Muken has 0, so none is measured yet.
The newest scored trade: sold $80k of SOPH on Oct 5, 2026, filed Oct 7, 2026, scored 29 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 11 sells worth $250k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SOPH: SOPHiA GENETICS SA
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 29Weak | SOPHiA GENETICS SA | $80k 9,838 shares | -1% | +111% from low-8% from high | |
| 20Weak | SOPHiA GENETICS SA | $3,515 422 shares | -0% | +140% from low-8% from high | |
| 27Weak | SOPHiA GENETICS SA | $51k 9,838 shares | -1% | +77% from low-11% from high | |
| 15Weak | SOPHiA GENETICS SA | $2,270 422 shares | -0% | +79% from low-3% from high | |
| 15Weak | SOPHiA GENETICS SA | $3,501 761 shares | -0% | +64% from low-15% from high | |
| 15Weak | SOPHiA GENETICS SA | $3,955 760 shares | -0% | +87% from low-6% from high | |
| 15Weak | SOPHiA GENETICS SA | $14k 2,800 shares | -0% | +78% from low-10% from high | |
| 21Weak | SOPHiA GENETICS SA | $38k 8,129 shares | -1% | +69% from low-15% from high | |
| 15Weak | SOPHiA GENETICS SA | $23k 4,736 shares | -1% | +83% from low-12% from high | |
| 15Weak | SOPHiA GENETICS SA | $24k 5,024 shares | -1% | +86% from low-10% from high | |
| 15Weak | SOPHiA GENETICS SA | $5,671 1,183 shares | -0% | +83% from low-12% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 5, 2026 | SOPH SOPHIA GENETICS SA | 9,838 0.01% of outstanding | $79k | Oct 5, 2026 | $55k |
| Sep 21, 2026 | SOPH SOPHIA GENETICS SA | 422 0.00% of outstanding | $3,456 | Sep 21, 2026 | $54k |
| Jul 6, 2026 | SOPH SOPHIA GENETICS SA | 9,838 0.01% of outstanding | $53k | Jul 6, 2026 | $97k |
| Jun 22, 2026 | SOPH SOPHIA GENETICS SA | 422 0.00% of outstanding | $2,304 | Jun 22, 2026 | $107k |
| May 19, 2026 | SOPH SOPHIA GENETICS SA | 761 0.00% of outstanding | $3,569 | May 19, 2026 | $109k |
| Apr 20, 2026 | SOPH SOPHIA GENETICS SA | 760 0.00% of outstanding | $4,013 | Apr 20, 2026 | $109k |
| Apr 6, 2026 | SOPH SOPHIA GENETICS SA | 20,689 0.03% of outstanding | $104k | Apr 6, 2026 | $13k |
| Mar 19, 2026 | SOPH SOPHiA GENETICS SA | 1,183 0.00% of outstanding | $5,809 | Mar 19, 2026 | $45k |
| Feb 19, 2026 | SOPH SOPHIA GENETICS SA | 760 0.00% of outstanding | $3,671 | Feb 19, 2026 | $45k |
| Jan 20, 2026 | SOPH SOPHIA GENETICS SA | 760 0.00% of outstanding | $4,142 | Jan 20, 2026 | $44k |
| Jan 5, 2026 | SOPH SOPHIA GENETICS SA | 6,221 0.01% of outstanding | $29k | Jan 5, 2026 | $48k |
| Dec 29, 2025 | SOPH SOPHIA GENETICS SA | 1,689 0.00% of outstanding | $7,769 | Dec 26, 2025 | $117k |
| Oct 3, 2025 | SOPH SOPHIA GENETICS SA | 13,486 0.02% of outstanding | $60k | Oct 3, 2025 | $34k |
| Jun 20, 2025 | SOPH SOPHIA GENETICS SA | 14,509 0.02% of outstanding | $44k | Jun 20, 2025 | $41k |
| Mar 19, 2025 | SOPH SOPHIA GENETICS SA | 15,303 0.02% of outstanding | $49k | Mar 19, 2025 | $20k |
| Dec 19, 2024 | SOPH SOPHIA GENETICS SA | 6,762 0.01% of outstanding | $23k | Dec 19, 2024 | $20k |
| Nov 19, 2024 | SOPH SOPHiA GENETICS SA | 1,485 0.00% of outstanding | $4,901 | Nov 19, 2024 | $18k |
| Oct 22, 2024 | SOPH SOPHiA GENETICS SA | 1,484 0.00% of outstanding | $4,897 | Oct 22, 2024 | $18k |
| Oct 4, 2024 | SOPH SOPHiA GENETICS SA | 3,236 0.00% of outstanding | $10k | Oct 4, 2024 | $53k |
| Sep 19, 2024 | SOPH SOPHiA GENETICS SA | 2,969 0.00% of outstanding | $13k | Sep 19, 2024 | $57k |
| Aug 19, 2024 | SOPH SOPHiA GENETICS SA | 810 0.00% of outstanding | $2,705 | Aug 19, 2024 | $61k |
| Jul 19, 2024 | SOPH SOPHiA GENETICS SA | 808 0.00% of outstanding | $3,725 | Jul 18, 2024 | $65k |
| Jul 9, 2024 | SOPH SOPHIA GENETICS SA | 3,378 0.01% of outstanding | $15k | Jul 9, 2024 | $64k |
| Jul 5, 2024 | SOPH SOPHiA GENETICS SA | 6,500 0.01% of outstanding | $30k | Jul 5, 2024 | $196k |
| Jun 20, 2024 | SOPH SOPHiA GENETICS SA | 1,484 0.00% of outstanding | $7,405 | Jun 20, 2024 | $190k |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -9,838 | $8.13 | $80k | 660,391 | 8 d ago |
| Sep 21, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -422 | $8.33 | $3,515 | 670,229 | 23 d ago |
| Jul 6, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -9,838 | $5.22 | $51k | 670,651 | Jul 7, 2026 |
| Jun 22, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -422 | $5.38 | $2,270 | 680,489 | Jun 23, 2026 |
| May 19, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -761 | $4.60 | $3,501 | 680,911 | May 20, 2026 |
| Apr 20, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -760 | $5.20 | $3,955 | 681,672 | Apr 21, 2026 |
| Apr 14, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -2,800 | $4.96 | $14k | 682,432 | Apr 16, 2026 |
| Apr 10, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -3,687 | $4.69 | $17k | 689,674 | Apr 14, 2026 |
| Apr 13, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -4,442 | $4.77 | $21k | 685,232 | Apr 14, 2026 |
| Apr 8, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -2,786 | $4.84 | $13k | 695,311 | Apr 10, 2026 |
| Apr 9, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -1,950 | $4.74 | $9,239 | 693,361 | Apr 10, 2026 |
| Apr 6, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -2,600 | $4.85 | $13k | 700,521 | Apr 8, 2026 |
| Apr 2, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Ordinary Shares | +431,211 | $0.00 | $0 | 703,121 | Apr 8, 2026 |
| Apr 7, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -2,424 | $4.87 | $12k | 698,097 | Apr 8, 2026 |
| Apr 2, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Share Option (Right to Buy)derivative | +628,743 | $0.00 | $0 | 628,743 | Apr 8, 2026 |
| Apr 2, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Ordinary Shares | +431,211 | $0.00 | $0 | 431,211 | Apr 3, 2026 |
| Apr 2, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Share Option (Right to Buy)derivative | +628,743 | $0.00 | $0 | 628,743 | Apr 3, 2026 |
| Mar 19, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -1,183 | $4.79 | $5,671 | 271,910 | Mar 20, 2026 |
Questions about Ross Muken
Answered from the filings on this page, as of the latest one.
Is Ross Muken buying or selling?
In the last 12 months Ross Muken reported 0 open-market buys worth $0 and 11 open-market sells worth $250k on SEC Form 4; the latest was sold $80k of SOPH on Oct 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Ross Muken's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ross Muken has 0.
Where does Ross Muken file Form 4?
Ross Muken has filed Form 4 at SOPH (SOPHiA GENETICS SA) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.